FDA
-
healthTexas Invests $100 Million in Ibogaine Research for Addiction and PTSD
Texas commits $100 million to ibogaine research, exploring its potential to treat addiction, PTSD, and other medical conditions, signaling a major shift in therapeutic development.
-
healthNovo Nordisk Unveils Higher-Dose Semaglutide for Weight Loss
Novo Nordisk introduces a new 7.2 mg semaglutide injection, offering adults an enhanced therapeutic option for weight management and potential for greater loss.
-
healthEli Lilly’s Orforglipron Wins FDA Approval for Weight Loss
The FDA approved Eli Lilly's once-daily pill for chronic weight management in adults with obesity or related conditions.
-
healthFDA Approves Eli Lilly’s Oral GLP-1 Weight-Loss Pill Foundayo
The FDA has fast-tracked approval of Foundayo, Eli Lilly’s once-daily oral GLP-1 pill for obesity and overweight adults with comorbidities, following rapid clinical results and safety warnings.
-
healthRFK Jr. Pushes for Reversal of Banned Peptide Regulations
RFK Jr. advocates lifting FDA restrictions on 14 peptides with no proven efficacy and documented safety risks, sparking outcry from medical experts.
-
healthImmunotherapy Revolutionizes Bladder Cancer Treatment
An overview of how immunotherapy is used to treat urothelial bladder cancer, the most common bladder cancer type in the U.S.
-
healthFDA Cracks Down on Biologics Marketing Over Misleading Claims
The FDA issues untitled letters to four major pharma firms for promoting unapproved survival outcomes in biologic therapies, signaling a sharp uptick in enforcement.
-
healthJimini Health Raises $17M to Supervise AI Mental Health Chatbot
Jimini Health secures $17M to deploy Sage, a clinically supervised AI chatbot that supports patients between therapy sessions-offering a safer alternative to unregulated general-purpose bots.